Report Details:
15 Companies Covered
85 Pages
Tumor Ablation Market Report Highlights
The tumor ablation market reached an estimated USD 1.88 Billion in 2025 and is projected to grow from USD 2.09 Billion in 2026 to USD 5.35 Billion by 2035, registering a CAGR of 11.0% during the forecast period.
MRFR recognizes the following companies as the key players in the global tumor ablation market— SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany).
Tumor ablation is a treatment that destroys liver tumors by the use of a needle. These techniques can be used in small tumors and surgery is not possible in the patient. Ablation is an effective technique for tumors no longer than 3 cm across as well as slightly larger tumors such as 1 to 2 inches, or 3 to 5 cm across, it can be used along with embolization. Because ablation can be destroyed normal tissue around the tumor. The growth of tumor ablation is driven by the rising demand for minimally invasive tumor ablation techniques. However, side effect and complications associated with tumor ablation is likely to restrain the market growth.
Segment Analysis
The global tumor ablation market is segmented into technology, treatment, application, end-user, and region. The technology segment is further segmented into radiofrequency, microwave, irreversible electroporation, cryoablation, others. The treatment segment is further sub-segmented into surgical ablation, percutaneous ablation, laparoscopic ablation. The application segment is further sub-segmented into liver cancer, lung cancer, kidney cancer, and others. The end-user segment is further sub-segmented into hospitals and clinics, specialty centers, others.
Tumor Ablation Regional Report Analysis
The global tumor ablation market, based on region, has been divided into North America, Europe, Asia-Pacific, Rest of the World.
North America accounted for the largest market share of about 40.29% in 2020, owing to the advances in percutaneous ablation, growing demand for radiofrequency ablation for hepatocellular carcinoma, increasing geriatric population, and growing tumor-related issues among the population aged 65 years and above. According to the National Cancer Institute, in 2020, the US constitutes 1,806,590 new cases of cancer, and the country also recorded a total death of 606,520 cancer patients. However, the advancement in tumor treating techniques has increased the ratio of cancer survivors. According to the American Cancer Society, Inc., the total number of US. -based male cancer survivors in 2019 was 8,138,790, whereas the number of US-based female cancer survivors was accounted to be 8,781,580. In addition, the organization had also estimated the number of male and female cancer survivors to rise by 2030.
Europe is the second-largest market for tumor ablation due to the emergence of standardized methods and tools for tumor ablation treatment, growing demand for surgery radiotherapy and chemotherapy for early detected tumors, and increasing cases of various cancer among mid-aged and geriatric population and rising consumption of unhealthy and carcinogenic products. In addition, the government authorities have introduced early detection guidelines, screening programs, and vaccination coverage to increase the survival rate of the patients. Among the different types of cancers, lung cancer has the highest mortality rate, followed by colorectal cancer. Other factors that support the increasing demand for tumor ablation treatment include infections, obesity, occupational risk, and high exposure to UV. Moreover, according to WHO, Europe contributes about one-quarter of global cancer patients with 3.7 million new patients per year.
Asia-Pacific is expected to grow significantly in the tumor ablation market owing to the increasing consumption of carcinogenic products such as alcohol and betel nut, limited intake of fruits and vegetables, a revelation to indoor and outdoor air pollution, and rise in exposure to chemical pollutants across the region. Countries such as China are practicing microwave technology to treat lung tumors. Patients across the region suffering from non-small cell lung cancer (NSCLC) are being treated using microwave ablation technology.
The Rest of the World is expected to witness a rise in tumor ablation treatment. The increasing use of tobacco products and the high prevalence of smoking across the Middle East and North Africa (MENA) region activate oncogenes, further developing different types of tumors. Increasing tests for tumor molecular characterization of lung cancer across the region is expected to drive the tumor ablation market. The rising number of hepatic tumors among the Rest of the World population is generating opportunities for the industry players. Moreover, the healthcare centers in Latin America are practicing different techniques to treat patients suffering from various tumors. In addition, the high consumption of tobacco-based products across the territory is the major reason for tumor formation.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Tumor Ablation Market Research Report
Key Findings of the Study
• By Technology
- Radiofrequency ablation accounted for 35.5% of the Tumor Ablation Market in 2025, reflecting its installed-base advantage across community hospitals.
- Histotripsy is forecast to expand at a 12.3% CAGR through 2035, the fastest rate among all modalities.
- Microwave ablation reached approximately USD 0.49 Billion in 2025, driven by shorter procedure times.
• By Application
- Liver indications commanded 36.2% of the Tumor Ablation Market value in 2025.
- Lung tumor applications are growing at an 11.7% CAGR, supported by navigation bronchoscopy integration.
• By End User
- Hospitals retained a 50.0% revenue share of the Tumor Ablation Market in 2025.
- Cancer centers are advancing at a 12.8% CAGR as payer-credentialed interventional oncology programs expand.
• By Region
- North America generated 45.5% of global revenue in 2025.
- Asia-Pacific is accelerating at a 12.3% CAGR through 2035.
